Trump doubles down on trade with new pharma tariffs and a metals duty reset

President Donald Trump on April 2 imposed a new tariff regime on patented pharmaceutical imports and rewrote how the United States applies Section 232 duties to steel, aluminum, and copper products, deepening a trade strategy that the White House says is aimed at national security, domestic production, and supply chain control. The measures were announced exactly one year after Trump’s original “Liberation Day” tariff push and follow the collapse of the broader International Emergency Economic Powers Act tariff framework that the U.S. Supreme Court struck down in February.

Under the pharmaceutical proclamation, the administration said patented pharmaceuticals and associated pharmaceutical ingredients would face a 100% ad valorem duty unless manufacturers either secure agreements with the U.S. government on pricing and onshoring or qualify for lower rates through specific trade arrangements. The White House framed the move as the outcome of a Section 232 investigation, which found that imports of patented pharmaceuticals and active pharmaceutical ingredients were being brought into the United States in quantities and under circumstances that threaten national security.

The formal structure of the drug tariff is more layered than the headline number suggests. The proclamation states that imports of patented pharmaceuticals listed in Annex I will generally face a 100% duty, while companies with onshoring plans approved by the Secretary of Commerce will pay 20%, rising to 100% on April 2, 2030. Companies that have fully executed or are negotiating agreements on most-favored-nation pricing and onshoring of production and research and development can receive a zero-tariff outcome, while products from the European Union, Japan, the Republic of Korea, Switzerland and Liechtenstein are set at 15%, and products from the United Kingdom are set at 10% with a possible future reduction to zero under a separate arrangement.

The administration also drew a bright line between patented medicines and generic products. The April 2 proclamation explicitly states that generic pharmaceuticals and associated ingredients, including biosimilar products, will not be adjusted under Section 232 at this time. Reuters separately reported that large pharmaceutical companies would have 120 days before the full 100% tariff applies, while smaller producers would have 180 days. That timeline matters because it gives multinational drugmakers a short but meaningful compliance window to negotiate, localize manufacturing, or seek carve-outs.

Why did Donald Trump impose pharmaceutical tariffs through Section 232 national security authority?

The White House justification rests heavily on supply-chain vulnerability and manufacturing dependence. The pharmaceutical proclamation says that, as of 2025, about 53% of patented pharmaceutical products distributed in the United States were produced outside the country, and only 15% of patented active pharmaceutical ingredients by volume were domestically produced for the U.S. market. The proclamation further argues that patented pharmaceuticals are essential for both military and civilian healthcare, especially in areas such as cancer, rare disease, autoimmune disorders, and infectious diseases.

That framing is important because it moves the administration’s tariff policy away from a purely deficit-based or reciprocity-based trade argument and into a national security and industrial resilience narrative. Reuters reported that the new drug tariffs are meant in part to rebuild duties lost after the Supreme Court invalidated Trump’s broader IEEPA-based tariff structure. In other words, the April 2 measures are not simply another round of headline trade pressure. They are also a legal and policy pivot toward authorities that the administration appears to view as more durable.

The metals changes reflect a similar tactical shift. Trump did not remove Section 232 tariffs on steel, aluminum, or copper. Instead, he altered how many derivative products are taxed and how valuations are calculated. Reuters reported that the administration kept the 50% tariff on core commodity imports of steel, aluminum, and copper, but changed the methodology so the rate would apply to the U.S. sales price of the metals rather than the declared import value, which officials said had often been kept artificially low.

How do the new steel, aluminum, and copper tariff rules change the cost of finished goods imports?

For derivative goods, the April 2 metals proclamation creates a more standardized system. The White House states that full-value tariffs on aluminum and steel articles, certain copper articles, and certain aluminum and steel derivative articles will remain at 50% in some cases, but that full-value tariffs on certain copper articles and certain aluminum and steel derivative articles will generally be set at 25%. The proclamation also sets lower rates for some United Kingdom-origin products and for articles made entirely with U.S.-origin metal inputs.

Reuters described the practical effect as a halving of the duty rate to 25% on many derivative products made with steel, aluminum, and copper, with tariffs dropped entirely for products with minimal metal content. At the same time, Reuters reported that the White House would reduce duties on certain metal-intensive industrial and power-grid equipment to 15% through 2027 to support a broader industrial and data-center build-out. Those changes are scheduled to take effect just after midnight on April 6, 2026.

The White House proclamation also spells out a more detailed structure than the simplified public summary. It states that products listed in Annex I-B will generally face a 25% additional duty from April 6, while certain products listed in Annex III will be subject, through December 31, 2027, to a rate determined by their existing Column 1 tariff treatment, with the combined duty effectively reaching 15% for products whose ordinary rate is below that threshold. The proclamation also removes some products from the derivative list entirely.

The economic logic behind the redesign is administrative as much as strategic. Reuters reported that the old derivative-products regime had created compliance difficulties because importers had to calculate metal content across thousands of products, ranging from tractor parts to stainless steel sinks and railroad equipment. The White House argues that the new framework simplifies the tariff regime while reducing opportunities for valuation manipulation. Whether businesses experience it as simplification or simply as a new cost layer will likely depend on sector, product mix, and sourcing footprint.

What do the April 2 tariff announcements reveal about Donald Trump’s broader trade strategy in 2026?

The April 2 actions show that Trump is not retreating from tariffs after the courts limited his earlier program. Instead, the administration is leaning harder on sector-specific national security tools and negotiated bilateral arrangements. The pharmaceutical order uses company-by-company and country-by-country differentiation, while the metals proclamation narrows and recalibrates tariffs rather than abandoning them. Both decisions suggest a more targeted version of the same underlying trade doctrine: use tariffs to force production, pricing, and supply-chain decisions back toward the United States.

Institutional reaction was divided almost immediately. Reuters reported that the U.S. Chamber of Commerce warned that the new pharmaceutical tariff structure could raise healthcare costs for American families and that the metals revisions could further raise prices for consumers while adding pressure to manufacturing, construction, and energy. Reuters also reported that the Steel Manufacturers Association welcomed the updated metals framework, saying it had been “right-sized” and that the valuation methodology would keep tariffs targeted at supporting domestic steel revival.

For global trade partners, the April 2 announcements also underscore how differentiated U.S. trade policy has become under Trump’s second term. Pharmaceutical rates now vary by company behavior and by trade arrangement. Metals duties vary by product class, metal content, origin, and in some cases by whether the input metal was produced in the United States or the United Kingdom. That complexity may give Washington more bargaining room, but it also makes the tariff landscape harder for exporters, customs specialists, and multinational manufacturers to model.

The biggest immediate policy implication is that the United States has moved from a broad tariff shock model to a more selective pressure model. Instead of hitting nearly all trading partners with sweeping reciprocal duties, the administration is now applying trade pressure through sector-specific legal authorities tied to national security investigations and negotiated compliance pathways. That does not make the system lighter. In some industries, it may make it more durable and more intrusive. On April 2, the message from the White House was clear enough: tariffs remain central to Trump’s economic and industrial policy, and pharmaceuticals and metals are now among the clearest proof points of that approach.

What do Donald Trump’s new pharma and metals tariffs mean for global trade and U.S. allies?

• President Donald Trump imposed a new Section 232 tariff regime on patented pharmaceutical imports, with a headline 100% duty but lower or zero rates available through onshoring and pricing agreements or specific trade arrangements.
• Generic pharmaceuticals and biosimilars were not included in the April 2 Section 232 pharmaceutical tariff action.
• The White House kept the 50% Section 232 duty on core steel, aluminum, and copper imports, while moving many derivative products to a 25% full-value tariff structure and reducing some industrial and grid equipment duties to 15% through 2027.
• The administration is using more targeted national security authorities after the U.S. Supreme Court struck down the broader IEEPA-based tariff system in February 2026.
• The policy direction points to a more selective but still aggressive U.S. trade model, with company-specific and country-specific tariff outcomes increasingly tied to manufacturing location, pricing commitments, and negotiated trade frameworks.